-
1.发明授权SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS 有权用于治疗血管舒缩症状，雌激素受体的选择性调节剂
公开(公告)号：EP1709021B1
公开(公告)日：2010-08-04
申请号：EP05704874.6
申请日：2005-01-18
发明人： DALLY, Robert, Dean , DODGE, Jeffrey, Alan , FRANK, Scott, Alan , HINKLIN, Ronald, Jay , SHEPHERD, Timothy, Alan , WALLACE, Owen, Brendan
IPC分类号： C07D295/08 , C07D311/78 , C07D335/04 , C07D221/18 , A61K31/4453 , A61K31/4523 , A61K31/55 , A61P15/12
CPC分类号： C07D295/088 , C07D221/18 , C07D311/78 , C07D335/04
摘要： The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
-
2.发明授权TRANS-4-[[(5S)-5-[[[3,5-BIS(TRIFLUOROMETHYL)PHENYL]METHYL](2-METHYL-2H-TETRAZOL-5-YL)AMINO]-2,3,4,5-TETRAHYDRO-7,9-DIMETHYL-1H-1-BENZAZEPIN-1-YL]METHYL]-CYCLOHEXANECARBOXYLIC ACID 有权TRANS-4 - [[（5S）-5 - [[[3,5-双（三氟甲基）苯基]甲基]（2-甲基-2H-四唑-5-基）氨基] -2,3,4,5 - 四氢-7,9- DYMETHYL -1H-1-苯并吖庚因-1-基]甲基]-CYCLOHEXANECARBONÄURE
公开(公告)号：EP2448933B1
公开(公告)日：2013-08-28
申请号：EP10728558.7
申请日：2010-06-28
IPC分类号： C07D403/12 , A61K31/55 , A61P9/10
CPC分类号： C07D403/12
-
3.发明授权SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP 有权选择性雌激素受体调节剂，AN苯磺酰基CONTAIN
公开(公告)号：EP1530470B1
公开(公告)日：2009-06-10
申请号：EP03765254.2
申请日：2003-07-16
发明人： DALLY, Robert, Dean , DODGE, Jeffrey, Alan , FRANK, Scott, Alan , JONES, Scott, Alan , SHEPHERD, Timothy, Alan , WALLACE, Owen, Brendan , FONG, Kin, Chiu , HUMMEL, Conrad, Wilson , LEWIS, Geroge, Sal
IPC分类号： A61K31/4453 , A61P5/32 , C07D295/08 , C07D333/56 , C07D333/72 , C07D295/12 , C07D333/64
CPC分类号： C07D295/088 , C07D295/13 , C07D333/56 , C07D333/64 , C07D333/72 , C07D409/02
摘要： The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
-
公开(公告)号：EP3996713A1
公开(公告)日：2022-05-18
申请号：EP20751396.1
申请日：2020-07-06
发明人： ABURUB, Aktham , COATES, David, Andrew , FRANK, Scott, Alan , KERR, Mark, Steven , ROTHHAAR, Roger, Ryan , VAID, Radhe, Krishan
IPC分类号： A61K31/444 , A61P25/06 , C07D401/06
-
5.发明公开SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP 有权选择性雌激素受体调节剂，AN苯磺酰基CONTAIN
公开(公告)号：EP1530470A1
公开(公告)日：2005-05-18
申请号：EP03765254.2
申请日：2003-07-16
发明人： DALLY, Robert, Dean , DODGE, Jeffrey, Alan , FRANK, Scott, Alan , JONES, Scott, Alan , SHEPHERD, Timothy, Alan , WALLACE, Owen, Brendan , FONG, Kin, Chiu , HUMMEL, Conrad, Wilson , LEWIS, Geroge, Sal
IPC分类号： A61K31/4453 , A61P5/32 , C07D295/08 , C07D333/56 , C07D333/72 , C07D295/12 , C07D333/64
CPC分类号： C07D295/088 , C07D295/13 , C07D333/56 , C07D333/64 , C07D333/72 , C07D409/02
摘要： The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
-
公开(公告)号：EP4410784A2
公开(公告)日：2024-08-07
申请号：EP24174898.7
申请日：2020-07-06
发明人： ABURUB, Aktham , COATES, David Andrew , FRANK, Scott, Alan , KERR, Mark, Steven , ROTHHAAR, Roger, Ryan , VAID, Radhe, Krishan
IPC分类号： C07D401/06
CPC分类号： C07D401/06 , A61K31/444 , A61P25/06 , C07C53/08
摘要： The present invention provides 2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
-
7.发明授权SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP 有权选择性雌激素受体调节剂，AN苯磺酰基CONTAIN
公开(公告)号：EP1530470B9
公开(公告)日：2010-04-07
申请号：EP03765254.2
申请日：2003-07-16
发明人： DALLY, Robert, Dean , DODGE, Jeffrey, Alan , FRANK, Scott, Alan , JONES, Scott, Alan , SHEPHERD, Timothy, Alan , WALLACE, Owen, Brendan , FONG, Kin, Chiu , HUMMEL, Conrad, Wilson , LEWIS, Geroge, Sal
IPC分类号： A61K31/4453 , A61P5/32 , C07D295/08 , C07D333/56 , C07D333/72 , C07D295/12 , C07D333/64
CPC分类号： C07D295/088 , C07D295/13 , C07D333/56 , C07D333/64 , C07D333/72 , C07D409/02
摘要： The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
-
公开(公告)号：EP1713770A1
公开(公告)日：2006-10-25
申请号：EP05704872.0
申请日：2005-01-18
IPC分类号： C07D209/32 , C07D295/08 , C07D311/58 , C07D311/60 , C07D333/64 , C07D333/68 , A61K31/4025 , A61K31/4523 , A61P5/30
CPC分类号： C07D209/14 , C07D295/084 , C07D311/58 , C07D311/60 , C07D333/64
摘要： The present invention relates to a selective estrogen receptor modulator selected from the group consisting of: (I) or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.
摘要翻译： 本发明涉及选自以下的选择性雌激素受体调节剂：（I）或其药用盐; 例如用于治疗子宫内膜异位和子宫平滑肌瘤。
-
公开(公告)号：EP1709023A1
公开(公告)日：2006-10-11
申请号：EP05704876.1
申请日：2005-01-18
IPC分类号： C07D295/08 , C07D335/02 , C07D409/04 , C07D333/64 , A61P5/00
CPC分类号： C07D295/088 , C07D333/64 , C07D335/02 , C07D409/04
摘要： The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.
摘要翻译： 本发明涉及式I的选择性雌激素受体调节剂或其药用酸加成盐; 例如用于治疗子宫内膜异位和子宫平滑肌瘤。
-
10.发明公开TRANS-4-[[(5S)-5-[[[3,5-BIS(TRIFLUOROMETHYL)PHENYL]METHYL](2-METHYL-2H-TETRAZOL-5-YL)AMINO]-2,3,4,5-TETRAHYDRO-7,9-DIMETHYL-1H-1-BENZAZEPIN-1-YL]METHYL]-CYCLOHEXANECARBOXYLIC ACID 有权反式-4 - [[（5S）-5 - [[[3,5-双（三氟甲基）苯基]甲基]（2-甲基-2H-四唑-5-基）氨基] -2,3,4,5- 四氢-7,9-二DYMETHYL -1H-1-苯并吖庚因-1-基]甲基]-CYCLOHEXANECARBONÄURE
公开(公告)号：EP2448933A1
公开(公告)日：2012-05-09
申请号：EP10728558.7
申请日：2010-06-28
IPC分类号： C07D403/12 , A61K31/55 , A61P9/10
CPC分类号： C07D403/12
摘要： Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol- 5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]- cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.015 秒)
